Full Press Release Details
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Tonix Pharmaceuticals Announces the Launch of the "Move Fibro
Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals
Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary,
launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating
condition with no new FDA-approved treatments in over 15 years.
"Millions of individuals impacted by fibromyalgia have suffered
in silence for far too long," said Thomas Englese, President of Tonix Medicines, Inc. "We believe that demonstrating our knowledge
of, and compassion for, their condition and validation of their experience is an important step toward meaningful progress. This campaign
is a reflection of our commitment to the community-both today and in the future."
"Fibromyalgia can make you feel invisible," said Sharon
Waldrop, a person with lived experience and Founder of the Fibromyalgia Association. "Initiatives like Move Fibro Forward help shine
a light on our experiences and encourage individuals impacted by fibromyalgia to seek education and resources."
For more information about the campaign, visit www.movefibroforward.com.
Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous
system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., approximately 90% of whom are women. Symptoms of fibromyalgia
include chronic widespread pain, nonrestorative sleep, fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction
and mood disturbances, including anxiety and depression. Individuals suffering from fibromyalgia struggle with their daily activities,
have impaired quality of life, and frequently are disabled. Physicians and patients report common dissatisfaction with currently marketed
Tonix Pharmaceuticals Holding Corp.
Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health
challenges. Tonix's development portfolio is focused on central nervous system (CNS) disorders, immunology, and infectious diseases.
Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, Inc. our wholly owned
commercial subsidiary, markets treatments for acute migraine.
This press release and further information about Tonix can be found
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast,"
"estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the
failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market
any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited
research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on
Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC") on March
18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Tonix Pharmaceuticals